Teva’s sunny forecast for crucial migraine drug Ajovy raises eyebrows on Wall Street

1st November 2018 Uncategorised 0

Teva’s new migraine drug Ajovy dominated conversation after Teva’s third-quarter earnings report, as analysts pounded executives for details about how rebates and discounts might hamper net sales. That’s no surprise, considering Teva is counting on the new drug to make up for faltering sales of generics and MS blockbuster Copaxone.

More: Teva’s sunny forecast for crucial migraine drug Ajovy raises eyebrows on Wall Street
Source: fierce